The promise of new drugs for schizophrenia treatment

Canadian Journal of Psychiatry

Volumn 42, Issue 3, 1997, Pages 265-273

  Tamminga, C A ^a,b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

clozapine; efficacy; new antipsychotic; olanzapine; risperidone; schizophrenia; sertindol e; side effects

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

HUMAN; REVIEW; SCHIZOPHRENIA;

EID: 0030958385     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379704200304     Document Type: Review

References (76)

1. Tamminga CT. Theneuropsychiatry of schizophrenia. In: Yodofsky S, editor. The third edition of the APA textbook of neuropsychiatry. Forthcoming.
2. Carpenter WT Jr, Buchanan RW. Schizophrenia. N Eng J of Med 1994;330:681-90.
3. Carpenter WT, Buchanan RW, Kirkpatrick B, Tamminga CA, Wood F. Strong inference, theory testing and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993;50:825-31.
4. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
5. Delay J, Deniker P. Le traitement des psychoses par une méthode neurolytique dérivée de l'hibernothérapie. In: Congrès des Médecins Aliénistes et Neurologistes de France. Luxembourg; 1952. p 497-502.
6. Carlsson A, Lindquist M. Effect of chlorpromazine and haloperidol on formation of3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologies and Toxicologica 1963;20:140-4.
7. 3H]haloperidol. Psychopharmacology Communications 1975;1:663-73.
8. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9.
9. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, and others. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 1984;225:728-31.
10. Pickar D, Labarca R, Doran AR. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 1986;43:669-76.
11. Walinder J, Skott A, Carlsson A, Roos BE. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. Arch Gen Psychiatry 1976;33:501-5.
12. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. Pharmacologie properties of (-)-3PPP (preclamol) in man. J Neural Transm 1992;88:165-75.
13. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, and others. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997. Forthcoming.
14. 2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63.
15. 4 receptors elevated in schizophrenia. Nature 1993;365:441-5.
16. Seeman P. Dopamine receptors and psychosis. Science and Medicine 1905;5:28-37.
17. Klein DF, Davis JM. Review of antipsychotic drug literature. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams & Wilkins; 1969. p 61-3.
18. Tamminga CA, Shirakawa O, Conley RR. Nontarget actions of neuroleptics. In: Brunello N., Mendlewicz J. Racagni G, editors. New generations of antipsychotic drugs: novel mechanisms of action. Volume 4. Basel: Karger; 1993. p 67-76.
19. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
20. 2 receptor. Nature 1988;336:783-7.
21. 3 receptor. Nature 1990;347:146-51.
22. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610.
23. 2-family receptors in schizophrenia: distribution and implications for treatment. Clin Neuropharmacol 1995;18 (3 Suppl):110S-120S.
24. Meador-Woodruff JH, Grandy DK, Van Tol HHM, Damask SP, Little KY, Civelli O, and others. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994;10:239-48.
25. 2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 1995;6:2505-12.
26. 2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 1996;7:1945-8.
27. Lahti RA, Figur LM, Piercy MF, Ruppel PL, Evans DL. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 1992;42:432-8.
28. Tamminga CA, Dannals RF, Frost J, Wong D, Wagner HN. Neuroreceptor and neurochemistry studies with positron emission tomography in psychiatric illness: promise and progress. In: Oldham JM, Riba MB, Tasman A, editors. American Psychiatric Press, Review of Psychiatry. Volume 12. Washington (DC): American Psychiatric Press; 1993. p 487-510.
29. Holcomb HH, Tamminga CA, Cascella NG, Thaker GK, Medoff DR, Gastineau EA, and others. Functional sites of neuroleptic drug action in human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:141-9.
30. Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP. Importance of pharmacologie control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res 1991;40:115-24.
31. Kane J, Honigfeld G, Singer J. Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
32. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hospital and Community Psychiatry 1992:43:700-3.
33. Meltzer HY, Burnet S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 1990;141:892-7.
34. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hospital and Community Psychiatry 1993;44:1145-9.
35. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992;160:5-11.
36. Carlsson M, Svensson A, Carlsson A. Synergistic interactions between muscarinic antagonists, adrenergic and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn Schmiedebers Arch Pharmacol 1991;343:568-73.
37. Casey DE. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology 1996;124:134-40.
38. Gao X-M, Hashimoto T, Cooper TB, Tamminga CA. The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. J Neural Transm 1996.
39. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. Neuroleptic-in-duced extra-pyramidal side effects: clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 1986;40:492-9.
40. Gelders Y, VandenBussche G, Reyntijens A, Janssen P. Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 1986;9:325-7.
41. Nicolaou NM, Garcia-Munoz M, Arbuthnott GW, Eccleston D. Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 1979;57:295-305.
42. Herve D, Simon H, Blanc G, LeMoal M, Glowinski J, Tassin JP. Opposite changes in dopamine utilization in nucleus accumbens and the frontal cortex after electrolytic lesion of the median raphe in the rat. Brain Res 1981;216:422-8.
43. Rasmussen K, Aghajanian GK. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT, binding affinity. Neuropsychopharmacology 1988;1:101-7.
44. Claghorn JC, Honigfeld G, Abuzzahab FS, and others. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-84.
45. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:18S-27S.
46. Borison R, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-72.
47. Marder SR. Risperidone, clinical development: North American results. Clin Neuropharmacol 1992;15:92A-93A.
48. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, and others. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [erratum]. J Clin Psychopharmacol 1993;13:149.
49. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55:102-6.
50. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, and others. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
51. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacolog 1996;124:87-94.
52. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
53. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-94.
54. Robertson GS, Fibiger HC. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105-10.
55. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exper Ther 1992;262:545-51.
56. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze: a comparative study between novel and reference antipsychotics. Psychopharmacologv 1996;124:126-33.
57. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine HGAP Study Group. Psychopharmacology 1996;124:159-67.
58. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23,
59. Keck PE, McElroy SL. Olanzapine: a novel antipsychotic medication. The Journal of New Developments in Clinical Medicine 1996;14:63-78.
60. Tollefson GD, Sanger TM. Negative symptoms: a path-analytic approach to the double-blind, placebo-and haloperidol-controlled clinical experience with olanzapine. Am J Psychiatry. Forthcoming.
61. Gao X-M, Sakai K, Tamminga CA. Chronic olanzapine or sertindole treatment results in reduced oral dyskinesias in rats compared to haloperidol [abstract]. Neuroscience Abstracts 1997 22:1087.
62. Sanchez C, Amt J, Dragsted N, Hyttel J, Lembol HL, Meier E, and others. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development Research 1991;22:239-50.
63. Bøgeso KP, Andersen K, Amt J, Frederiksen K, Hyttel J, Perregaard J, and others, Design of atypical antipsychotic drugs. In: Fog R, Gerlach J, Hemmingsen R, editors. Schizophrenia: an integrated view. Copenhagen: Munksgaard: 1995. p 361-75.
64. Jackson DM, Johansson C, Lindgren L. Dopamine receptor antagonism blocks amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 1994;48:465-71.
65. Fink-Jensen A, Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 1994;182:115-8.
66. VanKammen D, McEvoy J, Targum S, Kardatzki D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75.
67. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Morris DD, and others. A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 1997. Forthcoming.
68. Hale A, vander Burght M, Wehnert A, Sloth-Nielsen M. A European dose-range study comparing the efficacy, tolerability, and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. Presented at the American College of Neuropsychopharmacology Annual Meeting; 1996 December; San Juan, Puerto Rico.
69. Krystal J, D'Souza DC, Holgate KL, Staser JA, Silber CJ, Mack RJ, Sertindole: a multi-center, one year, haloperidol controlled trial assessing the long-term safety, efficacy and quality of life in stable schizophrenic patients. Presented at the American College of Neuropsychopharmacology Annual Meeting; 1996 December; San Juan, Puerto Rico.
70. Granneman GR, Wozniak P, Ereshefsky L, Silber C, Mack R. Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia. Presented at the American College of Neuropsychopharmacology Annual Meeting; 1996 December; San Juan, Puerto Rico.
71. Tandon R, Silber C, Mack R. The action of sertindole on negative symptoms in schizophrenia. American College of Neuropsychopharmacolgy Annual Meeting; 1996 Dec; San Juan, Puerto Rico.
72. Swann A, Daniel D, Silber C, Mack R. Long term cardiovascular safety of sertindole. Presented at the American College of Neuropsychopharmacology Annual Meeting; 1996 December; San Juan, Puerto Rico.
73. Goldstein JM, Arvanitis LA. ICI 204,636 (seroquel): a dihenzothiazepine atypical antipsychotic; review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Reviews 1995;1:50-73.
74. Borison RL, Arvanitis LA, Miller BG, US Seroquel Study Group. ICI204636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Clin Psychopharmacol 1996;16:158-69.
75. Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA. ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 1996;168:45-56.
76. Lahti AC, Lahti R, Tamminga CA. The new antipsychotics and experimental therapeutics. In: Breier A, editor. Advances in neuroleptic drugs. Washington (DC): American Psychiatric Press. Forthcoming.